Drug Trial Radar · NCT03567291
Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
228
Actual
Start
May 25, 2018
Primary completion
May 15, 2020
Study completion May 15, 2020
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- Collaborators
- Nuvelution TS Pharma, Inc.
- First posted
- Jun 25, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an otherwise open-label, single-arm study that includes a 2-week, double-blind, placebo controlled, randomized drug withdrawal period followed by a 3 week blinded maintenance or re-titration, and then a maintenance period. This study aims to evaluate the safety and efficacy of TEV-50717 tablets in patients with tics associated with TS who have previously completed participation in any of the parent studies.
Conditions
- Tourette Syndrome
Interventions
TEV-50717Drug
6, 9, and 12 mg oral tablets
PlaceboDrug
Placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Treatment Emergent Adverse Events (AEs) for Parts A & B CombinedTime frame: Day 1 to Week 55
- Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II)Time frame: Weeks 28 to 30
- Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total ScoreTime frame: Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55
- Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Self-reported Version) Total ScoreTime frame: Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55
- Change From Randomized Withdrawal Baseline (Week 28) in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score at Week 30Time frame: Week 28, Week 30
- Change From Randomized Withdrawal Baseline (Week 28) in the Children's Depression Inventory Second Edition (CDI-2; Self-reported Version) Total Score at Week 30Time frame: Week 28, Week 30
- Number of Participants Reporting Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55
- Number of Participants Reporting Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS) at Randomized Withdrawal Baseline Visit (Week 28) and Week 30Time frame: Week 28, Week 30
Locations
76 sites in 15 countries. Site status is shown where the registry gives one.
Teva Investigational Site 046-0104
Dothan, Alabama
Teva Investigational Site 046-0107
Rogers, Arkansas
Teva Investigational Site 046-0126
Anaheim, California
Teva Investigational Site 046-0101
Sacramento, California
Teva Investigational Site 046-0111
San Diego, California
Teva Investigational Site 060-0160
Gainesville, Florida
Teva Investigational Site 060-0166
Gulf Breeze, Florida
Teva Investigational Site 060-0161
Miami, Florida
Teva Investigational Site 046-0115
Orlando, Florida
Teva Investigational Site 060-0153
Orlando, Florida
Teva Investigational Site 046-0114
St. Petersburg, Florida
Teva Investigational Site 046-0116
Atlanta, Georgia
Teva Investigational Site 060-0155
Chicago, Illinois
Teva Investigational Site 060-0164
Chicago, Illinois
Teva Investigational Site 046-0133
Naperville, Illinois
Teva Investigational Site 046-0128
Boston, Massachusetts
Teva Investigational Site 060-0170
Bridgeton, Missouri
Teva Investigational Site 046-0110
Saint Charles, Missouri
Teva Investigational Site 046-0134
Lincoln, Nebraska
Teva Investigational Site 046-0109
Voorhees Township, New Jersey
Teva Investigational Site 046-0124
New York, New York
Teva Investigational Site 060-0154
New York, New York
Teva Investigational Site 046-0102
Rochester, New York
Teva Investigational Site 046-0106
Oklahoma City, Oklahoma
Teva Investigational Site 060-0169
Charleston, South Carolina
Teva Investigational Site 060-0156
Nashville, Tennessee
Teva Investigational Site 046-0113
Dallas, Texas
Teva Investigational Site 060-0163
Fort Worth, Texas
Teva Investigational Site 046-0108
Houston, Texas
Teva Investigational Site 046-0120
San Antonio, Texas
Teva Investigational Site 046-0105
Orem, Utah
Teva Investigational Site 046-0118
Petersburg, Virginia
Teva Investigational Site 060-0162
Everett, Washington
Teva Investigational Site 060-1407
Buenos Aires, Argentina
Teva Investigational Site 060-1402
Buenos Aires, Argentina
Teva Investigational Site 060-1403
La Plata, Argentina
Teva Investigational Site 060-1404
Mendoza, Argentina
Teva Investigational Site 060-1802
Liverpool, Australia
Teva Investigational Site 046-0201
Ajax, Ontario, Canada
Teva Investigational Site 046-0202
Ottawa, Ontario, Canada
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.